Detection of SARS-CoV-2 IgG Antibodies in Individuals Following Infection and Vaccination

M. Vedpathak, D. Shinde, Sonal Agarwal, N. Shaikh, Prathamesh Bagewadi
{"title":"Detection of SARS-CoV-2 IgG Antibodies in Individuals Following Infection and Vaccination","authors":"M. Vedpathak, D. Shinde, Sonal Agarwal, N. Shaikh, Prathamesh Bagewadi","doi":"10.51131/ijpccr/v4i2.23.10","DOIUrl":null,"url":null,"abstract":"To contain the SARS-CoV-2 infection a number of measures including vaccination had taken to reduce virus transmission and mortality. Protection from a viral infection is mainly achieved by virus-neutralizing antibodies which are produced after infection or vaccination. But to what degree these can induce the production of neutralizing antibodies is poorly understood. To determine the development of SARS-CoV-2 IgG antibody production against spike protein after infection and vaccination. A prospective study was conducted from July 2021 to December 2021 at tertiary care hospital, Solapur. Based on the evidence of previous SARS-CoV-2 infection and status of vaccination, a total of 150 participants above 18 years of age were enrolled. A blood sample was collected for the serum to perform an Enzyme-linked immunosorbent assay (ELISA) using the ErbaLisa COVID-19 IgG kit. Chi-square test for goodness of fit was used to analyze the data. In this study, we have assessed the development of protective immunity and it was found that 89.33% (134/150) of participants had a detectable level of SARS-COV-2 IgG antibodies. Also, in the present study the development of antibodies following infection, after a first and second dose of vaccination is compared, and observed that SARS-COV-2 IgG antibodies were detected in 88% of participants following infection, in 84% of participants after the first dose, and in 96% after the second dose. Effective vaccination is an essential solution to decrease - the severity, transmissibility and the emergence of new variants. Keywords: Covid antibody, Covid-19 immune response, SARS-CoV-2 IgG, vaccination","PeriodicalId":153371,"journal":{"name":"International Journal of Preclinical and Clinical Research","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Preclinical and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51131/ijpccr/v4i2.23.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

To contain the SARS-CoV-2 infection a number of measures including vaccination had taken to reduce virus transmission and mortality. Protection from a viral infection is mainly achieved by virus-neutralizing antibodies which are produced after infection or vaccination. But to what degree these can induce the production of neutralizing antibodies is poorly understood. To determine the development of SARS-CoV-2 IgG antibody production against spike protein after infection and vaccination. A prospective study was conducted from July 2021 to December 2021 at tertiary care hospital, Solapur. Based on the evidence of previous SARS-CoV-2 infection and status of vaccination, a total of 150 participants above 18 years of age were enrolled. A blood sample was collected for the serum to perform an Enzyme-linked immunosorbent assay (ELISA) using the ErbaLisa COVID-19 IgG kit. Chi-square test for goodness of fit was used to analyze the data. In this study, we have assessed the development of protective immunity and it was found that 89.33% (134/150) of participants had a detectable level of SARS-COV-2 IgG antibodies. Also, in the present study the development of antibodies following infection, after a first and second dose of vaccination is compared, and observed that SARS-COV-2 IgG antibodies were detected in 88% of participants following infection, in 84% of participants after the first dose, and in 96% after the second dose. Effective vaccination is an essential solution to decrease - the severity, transmissibility and the emergence of new variants. Keywords: Covid antibody, Covid-19 immune response, SARS-CoV-2 IgG, vaccination
感染和接种后个体SARS-CoV-2 IgG抗体检测
为控制SARS-CoV-2感染,采取了包括疫苗接种在内的一系列措施,以减少病毒传播和死亡率。对病毒感染的保护主要是通过感染或接种疫苗后产生的病毒中和抗体来实现的。但是在多大程度上这些能诱导产生中和抗体还不清楚。目的观察感染和接种后SARS-CoV-2刺突蛋白IgG抗体产生的发展情况。一项前瞻性研究于2021年7月至2021年12月在索拉普尔三级保健医院进行。根据既往SARS-CoV-2感染的证据和疫苗接种状况,共招募了150名18岁以上的参与者。采集血样用于血清,使用ErbaLisa COVID-19 IgG试剂盒进行酶联免疫吸附试验(ELISA)。采用卡方拟合优度检验对数据进行分析。在这项研究中,我们评估了保护性免疫的发展,发现89.33%(134/150)的参与者具有可检测水平的SARS-COV-2 IgG抗体。此外,在本研究中,比较了第一剂和第二剂疫苗接种后感染后抗体的发展,并观察到在感染后88%的参与者中检测到SARS-COV-2 IgG抗体,在第一剂疫苗接种后84%的参与者中检测到,在第二剂疫苗接种后96%的参与者中检测到。有效的疫苗接种是减少严重程度、传播力和新变种出现的基本解决办法。关键词:Covid抗体,Covid免疫应答,SARS-CoV-2 IgG,疫苗接种
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信